Bevacizumab for Corneal Neovascularization

Ophthalmology

Volumn 116, Issue 3, 2009, Pages 592-593

  Jacobs, Deborah S ^a   Lim, Mira ^a   Carrasquillo, Karen G ^a   Rosenthal, Perry ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; CLINICAL ARTICLE; CONTACT LENS; CORNEA NEOVASCULARIZATION; DYSAUTONOMIA; FEMALE; HUMAN; LETTER; MALE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; RHEUMATIC DISEASE; SKIN DEFECT; STEVENS JOHNSON SYNDROME; ULCER;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CORNEAL NEOVASCULARIZATION; EPITHELIUM, CORNEAL; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROGNOSIS; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 61349088590     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.10.011     Document Type: Letter

References (4)

1. Kim S.W., Ha B.J., Kim E.K., et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115 (2008) e33-e38
2. Romero-Rangel T., Stravrou P., Cotter J., et al. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 130 (2000) 25-32
3. Rosenthal P., Cotter J.M., and Baum J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. Am J Ophthalmol 130 (2000) 33-41
4. Schachat A.P., Chambers W.A., Liesgang T.J., and Albert D.A. Safe and effective. Ophthalmology 110 (2003) 2073-2074